According to a new report published by K D Market Insights, titled, “Hyperlipidemia Drugs Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global hyperlipidemia drugs market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The increasing prevalence of hyperlipidemia and related cardiovascular diseases. As sedentary lifestyles, unhealthy dietary habits, and rising obesity rates become more prevalent globally which are the major factors augmenting the growth of the global hyperlipidemia drugs market.
The increasing prevalence of hyperlipidemia, driven by sedentary lifestyles, unhealthy dietary habits, and rising obesity rates, fuels the demand for effective lipid-lowering drugs. As hyperlipidemia is a significant risk factor for cardiovascular diseases which is further expected to create ample growth opportunities for the global hyperlipidemia drugs market during the forecast period i.e., 2023-2032. Moreover, advancements in drug development and research contribute to the introduction of novel hyperlipidemia drugs with improved efficacy and safety profiles, is increasing has propelled market expansion. Favorable government initiatives and reimbursement policies, is expected to contribute towards the market growth during the period.
The North America region accounted for the largest share in the global hyperlipidemia drugs market in 2022. The region is further projected to continue dominating in the market and also register the highest CAGR in the market during the forecast period. This can be attributed to the high prevalence of hyperlipidemia in the region, rising incidence of obesity and cardiovascular diseases.
According to drug class, the statins segment accounted for the largest market share in the hyperlipidemia drugs market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
The global hyperlipidemia drugs market is segmented into drug class, end user and region. Based on drug class, the market is bifurcated into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination, others. Based on end user, it is classified into hospitals, specialty clinics, homecare, others
The global hyperlipidemia drugs market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).
Key Insights of Hyperlipidemia Drugs Market
- On the basis of drug class, the statins segment accounted for the largest market share in the hyperlipidemia drugs market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
- On the basis of region, North America accounted for the largest share in the global hyperlipidemia drugs market in 2022. The region is further projected to continue dominating in the market during the forecast period.
- On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.
Some of the major hyperlipidemia drugs companies profiled in the report include F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Amgen Inc., DAIICHI SANKYO COMPANY, LIMITED, Alnylam Pharmaceuticals, Inc., Esperion Therapeutics, Inc., and Formac Pharmaceuticals N.V.
Related Healthcare Reports :-
https://www.kdmarketinsights.com/reports/patient-handling-equipment-market/7095
https://www.kdmarketinsights.com/reports/bone-cement-and-glue-market/7058
https://www.kdmarketinsights.com/reports/atrial-fibrillation-market/7055
https://www.kdmarketinsights.com/reports/alexandrite-gemstone-lasers-market/7053
